Calistoga: A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents.
||Michael Grossbard, MD
| Time frame of study:
|Location of Study:
Beth Israel Medical Center
St.Luke's-Roosevelt Hospital Center
Continuum Cancer Research Program
CAL‑101 is an investigational drug. CAL-101 blocks some of the cell functions that cause indolent Non-Hodgkin Lymphoma (iNHL), a type of cancer, to grow and survive. By blocking these functions, CAL-101 may reduce or prevent iNHL from growing and surviving. The purpose of this study is to provide more information about whether CAL-101 is safe and effective for treating people with iNHL once their iNHL has become difficult to control with available therapies. CAL-101 is used in this study as part of a research process to find out if it could eventually be approved for more general use in persons with iNHL.
- Male and female of at least 18 years old
- Histologically confirmed diagnosis of B-cell indolent Non-Hodgkin Lymphoma (iNHL)
- Prior treatment with ≥2 prior chemotherapy
- Discontinuation of all other therapies (including radiotherapy or chemotherapy) for the treatment of iNHL 3 weeks before initiation of study treatment
Please call for more information.